Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jan 31;9(2):e70072.
doi: 10.1002/hem3.70072. eCollection 2025 Feb.

Cytopenic overt primary myelofibrosis at presentation: Analysis of outcomes in the prospective, real-world ERNEST-2 registry

Paola Guglielmelli  1 , Arianna Ghirardi  2 , Alessandra Carobbio  2   3 , Arianna Masciulli  2 , Lucrezia Morrone  1 , Barbara Mora  4 , Elisa Rumi  5 , Ana Triguero  6 , Maria C Finazzi  7 , Helna Pettersson  8 , Valentina Boldrini  1 , Daniele Vanni  5 , Alessandro Rambaldi  7 , Francesco Passamonti  4 , Alberto Alvarez-Larràn  6 , Bjorn Andreasson  8 , Alessandro M Vannucchi  1 , Tiziano Barbui  2
Affiliations

Cytopenic overt primary myelofibrosis at presentation: Analysis of outcomes in the prospective, real-world ERNEST-2 registry

Paola Guglielmelli et al. Hemasphere. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Paola Guglielmelli received fees for lectures and advisory boards from Novartis and GSK. Alessandro M. Vannucchi received fees for lectures and advisory boards from Novartis, GSK, AbbVie, AOP, and Italfarmaco. Barbara Mora fees for Lectures for Novartis and GSK, and Advisory Board for GSK. Francesco Passamonti received honoraria for lectures and advisory boards from Novartis, Bristol‐Myers Squibb/Celgene, Sierra Oncology, AbbVie, Janssen, Roche, AOP Orphan, Karyopharm, Kyowa Kirin, and MEI. Alessandro Rambaldi received fees for consultancies and participation in meetings, boards, and symposia sponsored by Amgen, Pfizer, Novartis, Kite‐Gilead, Jazz, Astellas, Abbvie, Incyte, and Omeros. Tiziano Barbui received Gsk research grant support from GSK, and fees for the advisory board of Italfarmaco, AOP, and Ionis, and for lectures from AOP. For Elisa Rumi, Alberto Alvarez‐Larràn, Daniele Vanni, Arianna Masciulli, Arianna Ghirardi, Alessandra Carobbio, Lucrezia Morrone, Valentina Boldrini, AT, Maria C. Finazzi, Helna Pettersson, and Bjorn Andreasson, no relevant conflicts of interest were declared.

Figures

Figure 1
Figure 1
The 10‐year cumulative incidence of death and progression to blast phase of the 559 patients with overt primary myelofibrosis, categorized according to the cytopenic (CyP) or myeloproliferative (MyP) phenotype, enrolled in the ERNEST registry. (A–C) Kaplan–Meier estimates of overall survival according to disease phenotype (cytopenic [CyP] vs. myeloproliferative [MyP]; A), the type of cytopenia (anemia [An], thrombocytopenia [Thr], and An+Thr; B) and the severity of anemia (moderate (An‐mod) or severe (An‐sev); C). (D–F) Curves represent the Cumulative Incidence Function of blast phase (BP) evolution for patients categorized as above. In this analysis, death was considered as a competing event.
See this image and copyright information in PMC

References

    1. Marcellino BK, Verstovsek S, Mascarenhas J. The myelodepletive phenotype in myelofibrosis: clinical relevance and therapeutic implication. Clin Lymphoma Myeloma Leuk. 2020;20(7):415‐421. - PubMed
    1. Tefferi A, Lasho TL, Jimma T, et al. One thousand patients with primary myelofibrosis: the Mayo Clinic experience. Mayo Clin Proc. 2012;87(1):25‐33. - PMC - PubMed
    1. Reynolds SB, Pettit K. New approaches to tackle cytopenic myelofibrosis. Hematology. 2022;2022(1):235‐244. - PMC - PubMed
    1. Palandri F, Breccia M, Mazzoni C, et al. Ruxolitinib in cytopenic myelofibrosis: response, toxicity, drug discontinuation, and outcome. Cancer. 2023;129(11):1704‐1713. - PubMed
    1. Reynolds SB, Pettit K. New approaches to tackle cytopenic myelofibrosis. Hematology. 2022;2022(1):235‐244. - PMC - PubMed

LinkOut - more resources